The French government is set to become a shareholder in Opella, a subsidiary of Sanofi that produces Doliprane, through Bpifrance, the public investment bank.

The proposed sale has garnered significant political attention due to Doliprane's status as France's best-selling painkiller, especially in light of past shortages during the COVID pandemic.

The transaction is contingent upon finalizing agreements, social processes, and customary statutory approvals, with an anticipated closing date in the second quarter of 2025 at the earliest.

Unions have voiced concerns that selling Opella to an American group could jeopardize the 1,700 jobs associated with the unit in France.

Despite receiving an improved offer from the French fund PAI Partners, Sanofi remains committed to negotiating exclusively with CD&R.

Armand has indicated that the government is exploring various options for Opella, including potential representation on its board of directors to ensure oversight.

Sanofi's CEO, Paul Hudson, stated that the company can now focus more on innovative solutions for patients with serious illnesses, reflecting a strategic shift following the sale.

This move comes as the sale of Opella to the American investment fund Clayton Dubilier & Rice (CD&R) is likely to proceed after the government secured necessary guarantees.

French Economy Minister Antoine Armand expressed satisfaction at securing guarantees for the maintenance and development of Opella in France, including commitments on employment and investment.

The government is actively seeking assurances from Sanofi and CD&R to preserve jobs and production levels at Opella, which has raised concerns among over 250 employees at the Lisieux plant.

Nicolas Dufourcq, CEO of Bpifrance, confirmed the bank's readiness to partner with the winning bidder and highlighted its legitimacy as a co-shareholder due to past health sector investments.

Government spokesperson Maud Bregeon emphasized that the aim is to obtain written commitments regarding employment and supply security without obstructing the sale.